Hospital
Beth Israel Deaconess Hospital Plymouth, INC.
Beth Israel Deaconess Hospital Plymouth, INC. was paid $35.03M by Medicaid between Jan 2018 and Dec 2024, across 324 billing codes. Its largest line is G0378, Hospital observation service, per hour — 12% of everything it billed.
33Billing provider infoBETH ISRAEL DEACONESS HOSPITAL PLYMOUTH, INC.
PLYMOUTH, MA 02360
PLYMOUTH, MA 02360
33aNPI1760598700assigned 08/22/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$35.03M
24GClaims1,128,804
24DCodes billed324
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#30 of 66
Median peer was paid$29.11M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 163,969 | $4.84M | |
| 2019 | 173,833 | $4.53M | |
| 2020 | 151,053 | $4.48M | |
| 2021 | 171,179 | $4.70M | |
| 2022 | 156,761 | $5.10M | |
| 2023 | 170,909 | $6.11M | |
| 2024incomplete | 141,100 | $5.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0378 | Hospital observation service, per hour | 12% | 25,441 | 13,188 | $4.13M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 27,316 | 24,929 | $4.00M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 23,828 | 22,014 | $3.70M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.1% | 14,342 | 12,834 | $2.48M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.2% | 11,082 | 7,993 | $1.46M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.6% | 18,413 | 5,841 | $1.26M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.6% | 3,386 | 2,804 | $1.25M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 8,503 | 7,894 | $942K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 7,006 | 6,644 | $925K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.4% | 1,452 | 1,419 | $833K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 13,520 | 12,275 | $737K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.0% | 4,943 | 4,045 | $713K |
312 more codes
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.6% | 13,957 | $547K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 15,903 | $528K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 3,134 | $479K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.4% | 426 | $479K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.1% | 2,486 | $392K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.1% | 1,541 | $390K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,122 | $340K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,453 | $321K |
| S9485 | Crisis intervention mental health services, per diem | <1% | 823 | $313K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,854 | $301K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 73,394 | $297K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 2,008 | $293K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 400 | $292K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 13,200 | $290K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,710 | $276K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,042 | $268K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 8,894 | $255K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 11,766 | $245K |
| 80053 | Comprehensive metabolic panel | <1% | 70,042 | $228K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,415 | $221K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,613 | $221K |
| 93971 | <1% | 1,352 | $199K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,032 | $195K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,397 | $192K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,771 | $182K |
| 97161 | <1% | 3,000 | $175K | |
| 59025 | Fetal non-stress test | <1% | 547 | $163K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 886 | $139K |
| 84484 | <1% | 17,712 | $135K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 8,335 | $131K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,454 | $123K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 593 | $112K |
| 81513 | <1% | 1,269 | $111K | |
| 83735 | <1% | 24,716 | $92K | |
| ATP14 | <1% | 11,951 | $88K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,266 | $85K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,761 | $85K |
| 80050 | General health panel | <1% | 5,691 | $85K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 775 | $84K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,397 | $77K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,185 | $77K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,636 | $74K |
| ATP15 | <1% | 9,367 | $68K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 453 | $67K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,561 | $64K |
| 85027 | <1% | 20,565 | $64K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,022 | $62K |
| 76830 | Ultrasound, transvaginal | <1% | 641 | $58K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,709 | $57K |
| 88342 | <1% | 2,101 | $55K | |
| 82607 | <1% | 7,176 | $54K | |
| 71250 | <1% | 1,509 | $52K | |
| 84703 | <1% | 9,631 | $52K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,388 | $51K |
| 83690 | <1% | 11,373 | $49K | |
| 80061 | Lipid panel | <1% | 17,084 | $49K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,246 | $48K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 676 | $48K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,528 | $48K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,350 | $46K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18,615 | $45K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,473 | $43K |
| 82728 | <1% | 5,698 | $43K | |
| 76642 | <1% | 484 | $41K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,510 | $41K |
| 87481 | <1% | 1,498 | $41K | |
| 86803 | <1% | 3,462 | $40K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 155 | $37K |
| 86780 | <1% | 2,877 | $36K | |
| 84439 | <1% | 7,239 | $36K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,112 | $36K |
| 84702 | <1% | 2,881 | $35K | |
| 86850 | <1% | 5,251 | $35K | |
| 93976 | <1% | 257 | $34K | |
| 93017 | <1% | 498 | $34K | |
| 86618 | <1% | 2,348 | $32K | |
| 83880 | <1% | 2,269 | $31K | |
| 73610 | <1% | 1,146 | $30K | |
| 73630 | <1% | 1,599 | $29K | |
| 96367 | <1% | 837 | $29K | |
| 87186 | <1% | 5,593 | $28K | |
| 80143 | <1% | 5,029 | $28K | |
| 85610 | <1% | 16,626 | $27K | |
| 87070 | <1% | 5,014 | $27K | |
| 82948 | <1% | 8,233 | $27K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 645 | $27K |
| 0001A | <1% | 947 | $26K | |
| 87480 | <1% | 1,465 | $26K | |
| 82248 | <1% | 17,935 | $25K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,503 | $24K |
| 81001 | <1% | 15,511 | $24K | |
| 84100 | <1% | 16,252 | $23K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,668 | $23K |
| 87510 | <1% | 1,462 | $23K | |
| 87081 | <1% | 4,107 | $23K | |
| 84466 | <1% | 3,489 | $23K | |
| 87660 | <1% | 1,465 | $23K | |
| 73562 | <1% | 432 | $21K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,129 | $21K |
| ATP08 | <1% | 6,059 | $21K | |
| 99218 | <1% | 393 | $21K | |
| 86317 | <1% | 660 | $20K | |
| 81025 | <1% | 3,613 | $18K | |
| 85379 | <1% | 2,930 | $17K | |
| 73130 | <1% | 893 | $17K | |
| 83540 | <1% | 4,863 | $17K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,191 | $17K |
| 85730 | <1% | 5,130 | $15K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,835 | $15K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,004 | $15K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 115 | $15K |
| 87340 | <1% | 1,744 | $14K | |
| 83605 | <1% | 2,213 | $13K | |
| 86900 | <1% | 5,380 | $13K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 91 | $13K |
| 87040 | <1% | 1,398 | $13K | |
| 86140 | <1% | 3,603 | $13K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,857 | $12K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 92 | $12K |
| 84153 | <1% | 989 | $12K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 41,317 | $12K |
| 87430 | <1% | 1,153 | $12K | |
| 81003 | <1% | 8,997 | $11K | |
| 86901 | <1% | 5,363 | $11K | |
| 87088 | <1% | 2,254 | $11K | |
| 73110 | <1% | 322 | $11K | |
| 82570 | <1% | 4,681 | $11K | |
| 73030 | <1% | 860 | $11K | |
| 0002A | <1% | 367 | $11K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,134 | $10K |
| 87150 | <1% | 361 | $10K | |
| 76536 | <1% | 76 | $10K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,727 | $10K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,920 | $10K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,018 | $10K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 37 | $9K |
| 86762 | <1% | 747 | $9K | |
| J2704 | Injection, propofol, 10 mg | <1% | 13,398 | $9K |
| 97760 | <1% | 128 | $9K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,249 | $8K |
| 90715 | <1% | 353 | $8K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 254 | $8K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,088 | $8K |
| 0012A | <1% | 356 | $8K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 149 | $8K |
| 85652 | <1% | 5,009 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 222 | $7K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 54 | $7K |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 1,603 | $7K |
| 82043 | <1% | 3,503 | $7K | |
| 82746 | <1% | 999 | $7K | |
| 87077 | <1% | 1,991 | $7K | |
| 87147 | <1% | 1,077 | $7K | |
| 0011A | <1% | 397 | $6K | |
| 97162 | <1% | 167 | $6K | |
| 72100 | <1% | 233 | $6K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 37 | $6K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 57 | $6K |
| 80076 | <1% | 3,073 | $6K | |
| ATP17 | <1% | 3,596 | $5K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,541 | $5K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 25 | $5K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 280 | $5K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,986 | $5K |
| 70486 | <1% | 80 | $5K | |
| 87641 | <1% | 226 | $4K | |
| 71271 | <1% | 138 | $4K | |
| 83970 | <1% | 454 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,003 | $4K |
| ATP16 | <1% | 666 | $4K | |
| 77080 | <1% | 174 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,210 | $4K |
| ATP03 | <1% | 1,698 | $4K | |
| 88341 | <1% | 42 | $4K | |
| 87205 | <1% | 1,552 | $4K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,032 | $4K |
| 82951 | <1% | 300 | $3K | |
| 73700 | <1% | 38 | $3K | |
| 12001 | <1% | 27 | $3K | |
| 70496 | <1% | 52 | $3K | |
| 74018 | <1% | 154 | $3K | |
| 76775 | <1% | 28 | $3K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 408 | $3K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 158 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 67 | $3K |
| 85007 | <1% | 1,552 | $3K | |
| ATP18 | <1% | 976 | $3K | |
| 87631 | <1% | 28 | $3K | |
| 86038 | <1% | 318 | $3K | |
| 87653 | <1% | 91 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 240 | $2K |
| 77066 | Tomosynthesis, mammo | <1% | 38 | $2K |
| 84481 | <1% | 281 | $2K | |
| 82950 | <1% | 516 | $2K | |
| 84156 | <1% | 1,093 | $2K | |
| 83615 | <1% | 1,719 | $2K | |
| 73080 | <1% | 41 | $2K | |
| 80164 | <1% | 540 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 288 | $2K |
| 82784 | <1% | 253 | $2K | |
| 73564 | <1% | 179 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 397 | $2K |
| 74160 | <1% | 25 | $2K | |
| 72141 | <1% | 28 | $2K | |
| 73140 | <1% | 13 | $2K | |
| 87807 | <1% | 157 | $2K | |
| 10060 | <1% | 13 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 14 | $2K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 130 | $1K |
| 93975 | <1% | 26 | $1K | |
| 97166 | <1% | 12 | $1K | |
| 96523 | <1% | 26 | $1K | |
| 77062 | <1% | 12 | $1K | |
| 82565 | <1% | 1,545 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 357 | $1K |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 165 | $1K |
| 82140 | <1% | 144 | $1K | |
| 88304 | <1% | 220 | $1K | |
| 82952 | <1% | 298 | $1K | |
| 88312 | <1% | 42 | $998.10 | |
| ATP09 | <1% | 296 | $995.60 | |
| 83550 | <1% | 241 | $964.63 | |
| 86308 | <1% | 86 | $934.42 | |
| 82105 | <1% | 81 | $918.09 | |
| 82550 | <1% | 1,216 | $847.34 | |
| 85045 | <1% | 407 | $844.76 | |
| 84550 | <1% | 436 | $842.85 | |
| ATP11 | <1% | 318 | $780.57 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 445 | $779.70 |
| 86334 | <1% | 127 | $755.38 | |
| 87640 | <1% | 188 | $732.67 | |
| 73502 | <1% | 80 | $728.45 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 181 | $667.96 |
| 93970 | <1% | 12 | $659.08 | |
| 94726 | <1% | 12 | $657.32 | |
| 36416 | <1% | 58 | $655.50 | |
| 96376 | <1% | 2,691 | $600.00 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 23 | $594.72 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 748 | $572.45 |
| 86756 | <1% | 73 | $552.72 | |
| 86706 | <1% | 68 | $511.12 | |
| 80178 | <1% | 275 | $510.92 | |
| 88313 | <1% | 95 | $506.34 | |
| 97164 | <1% | 17 | $503.92 | |
| 94729 | <1% | 12 | $492.96 | |
| 82172 | <1% | 29 | $491.86 | |
| 70498 | <1% | 42 | $447.20 | |
| ATP02 | <1% | 167 | $385.45 | |
| 86665 | <1% | 12 | $384.00 | |
| 83516 | <1% | 39 | $382.38 | |
| 94762 | <1% | 111 | $369.83 | |
| 76000 | <1% | 14 | $311.15 | |
| 82803 | <1% | 17 | $275.88 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 189 | $249.68 |
| 84145 | <1% | 14 | $240.10 | |
| 88142 | <1% | 12 | $221.76 | |
| 36591 | <1% | 114 | $192.32 | |
| 86431 | <1% | 39 | $183.00 | |
| 82947 | <1% | 32 | $172.14 | |
| 85018 | <1% | 67 | $170.43 | |
| 86664 | <1% | 12 | $161.88 | |
| 84403 | <1% | 13 | $159.32 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 114 | $158.89 |
| Q3014 | Telehealth originating site facility fee | <1% | 304 | $150.91 |
| 81015 | <1% | 140 | $135.27 | |
| 84460 | <1% | 311 | $131.39 | |
| 86592 | <1% | 37 | $123.86 | |
| ATP04 | <1% | 25 | $123.08 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 277 | $114.89 |
| 83525 | <1% | 12 | $105.28 | |
| ATP07 | <1% | 40 | $101.16 | |
| 80159 | <1% | 26 | $95.35 | |
| 82378 | <1% | 15 | $83.60 | |
| 80177 | <1% | 17 | $82.02 | |
| 87207 | <1% | 32 | $80.15 | |
| 84520 | <1% | 333 | $77.15 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 77 | $66.38 |
| 87184 | <1% | 14 | $49.77 | |
| 97597 | <1% | 47 | $41.54 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 463 | $37.39 |
| 82247 | <1% | 18 | $36.56 | |
| 84165 | <1% | 14 | $33.21 | |
| 82962 | <1% | 423 | $29.04 | |
| 73090 | <1% | 13 | $20.64 | |
| 82040 | <1% | 55 | $10.22 | |
| 73590 | <1% | 13 | $8.08 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 360 | $7.22 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 14 | $5.42 |
| 91300 | <1% | 732 | $5.34 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 38 | $3.20 |
| 91301 | <1% | 317 | $2.40 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 330 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 43 | $0.00 |
| 84450 | 0% | 497 | $0.00 | |
| 84155 | 0% | 16 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 25 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 18 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 19 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 87 | $0.00 |
| J3490 | Unclassified drugs | 0% | 313 | $0.00 |
| 96368 | 0% | 16 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 14 | $0.00 |
| 80055 | 0% | 32 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 99 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 29 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 12 | $0.00 |
| 99406 | 0% | 14 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 30 | $0.00 |
| 87493 | 0% | 29 | $0.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 26 | $0.00 |
| C9285 | Lidocaine 70 mg/tetracaine 70 mg, per patch | 0% | 21 | $0.00 |
| 0064U | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRADZEVICH, JASON (V. P. OF FINANCE AND CFO)
| Provider | Location | Paid |
|---|---|---|
| Beth Israel Deaconess Hospital Plymouth, INC. | Plymouth, MA | $11.55M |
| Beth Israel Deaconess Hospital Plymouth, INC. | Plymouth, MA | $875K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.